TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+21.98%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$679M
AUM Growth
+$8.14M
(+1.2%)
Cap. Flow
-$20M
Cap. Flow
% of AUM
-2.94%
Top 10 Holdings %
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
25
Reduced
15
Closed
25
Top Buys
| 1 |
InflaRx
IFRX
|
$12.9M |
| 2 |
Verastem
VSTM
|
$8.48M |
| 3 |
Atea Pharmaceuticals
AVIR
|
$7.57M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$5.98M |
| 5 |
ADMA Biologics
ADMA
|
$4.65M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$21.5M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$9.81M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$9.01M |
| 4 |
BLUE
bluebird bio
BLUE
|
$8.23M |
| 5 |
Moderna
MRNA
|
$7.29M |
Sector Composition
| 1 | Healthcare | 92.72% |
| 2 | Financials | 6.8% |
| 3 | Real Estate | 0.3% |
| 4 | Consumer Discretionary | 0.15% |
| 5 | Utilities | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Galapagos
GLPG
$2.06B
| $3.65M | 0.54% |
89,650
| – | – |
|
52
Phathom Pharmaceuticals
PHAT
$843M
| $3.58M | 0.53% |
+250,000
| New | +$3.58M |
|
|
PRDS
53
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $3.52M | 0.52% |
1,945,206
+1,645,206
| +548% | +$2.98M |
|
54
Insmed
INSM
$30.3B
| $3.51M | 0.52% |
166,203
| – | – |
|
55
Biohaven
BHVN
$1.71B
| $3.35M | 0.49% |
140,000
| – | – |
|
56
Fate Therapeutics
FATE
$115M
| $3.33M | 0.49% |
700,000
| – | – |
|
57
US Bancorp
USB
$75.5B
| $3.3M | 0.49% |
+100,000
| New | +$3.3M |
|
58
Aligos Therapeutics
ALGS
$75.1M
| $3.23M | 0.48% |
133,162
-3,830
| -3% | -$93K |
|
59
Nkarta
NKTX
$149M
| $3.03M | 0.45% |
1,385,829
-400,000
| -22% | -$876K |
|
|
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.89M | 0.43% |
+80,000
| New | +$2.89M |
|
61
ARS Pharmaceuticals
SPRY
$1.08B
| $2.74M | 0.4% |
409,463
| – | – |
|
62
CVB Financial
CVBF
$2.74B
| $2.66M | 0.39% |
200,000
| – | – |
|
63
Esperion Therapeutics
ESPR
$490M
| $2.57M | 0.38% |
1,850,000
| – | – |
|
|
TECX
64
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $2.57M | 0.38% |
225,417
+222,283
| +7,093% | +$2.53M |
|
|
TSVT
65
DELISTED
2seventy bio
TSVT
| $2.53M | 0.37% |
250,000
| – | – |
|
66
MEI Pharma
MEIP
$149M
| $2.38M | 0.35% |
361,084
+102,911
| +40% | +$677K |
|
|
EGRX
67
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $2.31M | 0.34% |
118,857
+38,857
| +49% | +$755K |
|
|
LIAN
68
DELISTED
LianBio American Depositary Shares
LIAN
| $2.19M | 0.32% |
962,022
+752,422
| +359% | +$1.72M |
|
69
Amylyx Pharmaceuticals
AMLX
$877M
| $2.16M | 0.32% |
100,000
| – | – |
|
70
Bankunited
BKU
$2.92B
| $2.16M | 0.32% |
100,000
| – | – |
|
71
Heron Therapeutics
HRTX
$204M
| $2.15M | 0.32% |
1,850,000
+1,300,000
| +236% | +$1.51M |
|
|
EQC
72
DELISTED
Equity Commonwealth
EQC
| $2.03M | 0.3% |
100,000
| – | – |
|
73
Arvinas
ARVN
$580M
| $1.99M | 0.29% |
80,000
| – | – |
|
74
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $1.71M | 0.25% |
400,000
+200,000
| +100% | +$854K |
|
75
Editas Medicine
EDIT
$225M
| $1.65M | 0.24% |
+200,000
| New | +$1.65M |
|